NASDAQ: CYTKCytokinetics Inc Stock
$31.00+1.16 (+3.89%)
Updated May 16, 2025
CYTK Price
$31.00
Fair Value Price
-$11.31
Market Cap
$3.70B
52 Week Low
$29.31
52 Week High
$61.40
P/E
-5.86x
P/B
-13.9x
P/S
247.81x
PEG
N/A
Dividend Yield
N/A
Revenue
$19.22M
Earnings
-$615.26M
Gross Margin
100%
Operating Margin
-2,996.11%
Profit Margin
-3,201.5%
Debt to Equity
-5.75
Operating Cash Flow
-$398M
Beta
1
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
CYTK Overview
Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure; and reldesemtiv, a skeletal muscle troponin activator, which is in Phase III clinical trial to treat amyotrophic lateral sclerosis and spinal muscular atrophy. The company also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy; and CK-3772271, a small molecule cardiac myosin inhibitor that is in Phase I clinical trial. Cytokinetics, Incorporated has a strategic alliance with Astellas Pharma Inc. The company was incorporated in 1997 and is headquartered in South San Francisco, California.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine CYTK's potential to beat the market
FStrong Sell
- Stocks with a Zen Rating of Strong Sell (F) had an average loss of -8.02% per year. Learn More
Zen Rating Component Grades
D
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
CYTK
Ranked#367 of 456
Ranked#367 of 456
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $46.01 | A | |
| $8.19 | A | |
| $63.31 | A |
Be the first to know about important CYTK news, forecast changes, insider trades & much more!
CYTK News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how CYTK scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
CYTK ($31.00) is overvalued by 374.08% relative to our estimate of its Fair Value price of -$11.31 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
CYTK ($31.00) is not significantly undervalued (374.08%) relative to our estimate of its Fair Value price of -$11.31 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
CYTK is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more CYTK due diligence checks available for Premium users.
Valuation
CYTK fair value
Fair Value of CYTK stock based on Discounted Cash Flow (DCF)
Price
$31.00
Fair Value
-$11.31
Undervalued by
374.08%
CYTK ($31.00) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
CYTK ($31.00) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
CYTK is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
CYTK price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-5.86x
Industry
-154.88x
Market
25.95x
CYTK price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
-13.9x
Industry
4.21x
CYTK's financial health
Profit margin
Revenue
$1.6M
Net Income
-$161.4M
Profit Margin
-10,220.1%
CYTK's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
CYTK's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$1.3B
Liabilities
$1.5B
Debt to equity
-5.75
CYTK's short-term assets ($956.05M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
CYTK's long-term liabilities ($1.37B) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
CYTK's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
CYTK's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$131.6M
Investing
$106.0M
Financing
$4.8M
CYTK's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
CYTK vs Biotech Stocks
Cytokinetics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.